Salarius Pharmaceuticals reports progress in LSD1 inhibitor study, merger with Decoy Therapeutics.
ByAinvest
Wednesday, Jul 9, 2025 8:34 am ET1min read
SLRX--
Salarius Pharmaceuticals reports progress in its Phase 1/2 clinical study evaluating seclidemstat for MDS and CMML. The company also advances its merger with Decoy Therapeutics. Two animal studies published in peer-reviewed journals provide insights into the role of LSD1 inhibition in hematologic and solid tumors. Salarius' seclidemstat is an orally bioavailable LSD1 inhibitor being evaluated for MDS and CMML treatment.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet